AU2018359237A1 - C5aR inhibitor reduction of urinary sCD163 - Google Patents

C5aR inhibitor reduction of urinary sCD163 Download PDF

Info

Publication number
AU2018359237A1
AU2018359237A1 AU2018359237A AU2018359237A AU2018359237A1 AU 2018359237 A1 AU2018359237 A1 AU 2018359237A1 AU 2018359237 A AU2018359237 A AU 2018359237A AU 2018359237 A AU2018359237 A AU 2018359237A AU 2018359237 A1 AU2018359237 A1 AU 2018359237A1
Authority
AU
Australia
Prior art keywords
individual
treatment
urinary
c5ar
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018359237A
Other languages
English (en)
Inventor
Petrus BEKKER
Jun Deng
Thomas J. Schall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2018359237A1 publication Critical patent/AU2018359237A1/en
Priority to AU2024202593A priority Critical patent/AU2024202593A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2018359237A 2017-10-31 2018-10-30 C5aR inhibitor reduction of urinary sCD163 Abandoned AU2018359237A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202593A AU2024202593A1 (en) 2017-10-31 2024-04-19 C5aR inhibitor reduction of urinary sCD163

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579716P 2017-10-31 2017-10-31
US62/579,716 2017-10-31
PCT/US2018/058134 WO2019089534A1 (en) 2017-10-31 2018-10-30 C5aR INHIBITOR REDUCTION OF URINARY sCD163

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202593A Division AU2024202593A1 (en) 2017-10-31 2024-04-19 C5aR inhibitor reduction of urinary sCD163

Publications (1)

Publication Number Publication Date
AU2018359237A1 true AU2018359237A1 (en) 2020-04-30

Family

ID=66326509

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018359237A Abandoned AU2018359237A1 (en) 2017-10-31 2018-10-30 C5aR inhibitor reduction of urinary sCD163
AU2024202593A Pending AU2024202593A1 (en) 2017-10-31 2024-04-19 C5aR inhibitor reduction of urinary sCD163

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202593A Pending AU2024202593A1 (en) 2017-10-31 2024-04-19 C5aR inhibitor reduction of urinary sCD163

Country Status (9)

Country Link
US (2) US20190134020A1 (https=)
EP (2) EP4671767A3 (https=)
JP (2) JP7789483B2 (https=)
KR (1) KR20200109297A (https=)
CN (1) CN111670185A (https=)
AR (1) AR113815A1 (https=)
AU (2) AU2018359237A1 (https=)
CA (1) CA3078732A1 (https=)
WO (1) WO2019089534A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801519A4 (en) 2018-06-07 2022-03-30 ChemoCentryx, Inc. DOSAGE AND EFFECTS OF C5A ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
SMT202400521T1 (it) 2018-11-30 2025-01-14 Chemocentryx Inc Formulazioni di capsula
CA3235574A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
CN114641288A (zh) 2019-11-08 2022-06-17 凯莫森特里克斯股份有限公司 补体成分C5a受体的无定形形式
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022093971A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
EP4262800A4 (en) * 2020-12-21 2024-11-20 ChemoCentryx, Inc. TREATMENT OF C3 GLOMERULOPATHY WITH A C5A INHIBITOR
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
PT2585064T (pt) * 2010-06-24 2017-08-08 Chemocentryx Inc Antagonistas do c5ar
NZ730123A (en) 2014-09-29 2023-05-26 Chemocentryx Inc Processes and intermediates in the preparation of c5ar antagonists
WO2016166357A2 (en) * 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
AU2017246228B2 (en) * 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists

Also Published As

Publication number Publication date
EP4671767A2 (en) 2025-12-31
CA3078732A1 (en) 2019-05-09
JP2021501159A (ja) 2021-01-14
JP7789483B2 (ja) 2025-12-22
KR20200109297A (ko) 2020-09-22
US20230105869A1 (en) 2023-04-06
AR113815A1 (es) 2020-06-17
EP4671767A3 (en) 2026-03-11
CN111670185A (zh) 2020-09-15
EP3704110A1 (en) 2020-09-09
AU2024202593A1 (en) 2024-05-09
JP2023133317A (ja) 2023-09-22
WO2019089534A1 (en) 2019-05-09
EP3704110A4 (en) 2021-08-04
US20190134020A1 (en) 2019-05-09
TW201922289A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
US20230105869A1 (en) C5aR INHIBITOR REDUCTION OF URINARY sCD163
JP7788814B2 (ja) Ｃ３腎症を処置する方法
CN101883567B (zh) 二氨基吩噻嗪的治疗用途
JP7747614B2 (ja) Ｐｄ－ｌ１阻害剤としてのインダン
JP2019011343A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
EP4560024A2 (en) Deuterated analogs of d-serine and uses thereof
EP3823627A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
TWI913215B (zh) 減少尿液sCD163之C5aR抑制劑
CN1305342A (zh) 降低高半胱氨酸和c－反应蛋白水平的方法
WO2002017969A2 (en) Reagents and methods for the diagnosis of cmv dissemination
HK1262045B (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK1262045A1 (en) Ccx168 for use in the treatment of c3 glomerulopathy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted